Arabinosyl-5-azacytosine

A novel nucleoside entering clinical trials

Jean L Grem, D. Dale Shoemaker, Daniel F. Hoth, Susan A. King, Jacqueline Plowman, Daniel Zaharko, Charles K. Grieshaber, Steadman D. Harrison, James C. Cradock, Brian Leyland-Jones

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Arabinosyl-5-azacytosine is a new compound which has been selected by the Division of Cancer Treatment, National Cancer Institute for clinical development as an antineoplastic agent based on its high degree of activity against a broad range of tumor types in preclinical studies. Therapeutic activity has been observed against murine and human leukemias, transplantable murine solid tumors, and human tumor xenografts. Arabinosyl-5-azacytosine exhibited a broader spectrum of activity against human solid tumors than cytosine arabinoside. Arabinosyl-5-azacytosine is phosphorylated to the nucleotide level by deoxycytidine kinase. Upon further anabolism to the triphosphate level, it can be incorporated into DNA. The mechanism of cytotoxicity is thought to be related to inhibition of DNA synthesis. Leukemic and solid tumor cell lines that are resistant to cytosine arabinoside due to deletion of deoxycytidine kinase activity are cross-resistant to arabinosyl-5-azacytosine. Unlike cytosine arabinoside, arabinosyl-5-azacytosine does not readily undergo deamination. Schedule dependence has been demonstrated in mice bearing L1210 leukemia, with superior activity seen with multiple doses administered on each treatment day compared to administration of larger but less frequently administered doses. From preliminary data in solid tumor models, however, antitumor activity did not appear to be superior with continuous infusion compared to that observed on a bolus schedule. Preclinial toxicology studies indicated that the bone marrow and gastrointestinal tract were the main target organs. A single large dose of arabinosyl-5-azacytosine could be tolerated by both mice and dogs. When administered as a continuous infusion, the toxicity was related to both the dose and duration of exposure, suggesting that toxicity resulted from a critical time above a threshold concentration as opposed to the total area under the concentration-time curve. Phase I clinical trials have been initiated to determine the maximum tolerated dose on a low dose continuous infusion schedule for 72 hours and also on a high dose short infusion daily times five schedule.

Original languageEnglish (US)
Pages (from-to)315-328
Number of pages14
JournalInvestigational New Drugs
Volume5
Issue number4
DOIs
StatePublished - Dec 1 1987

Fingerprint

fazarabine
Nucleosides
Clinical Trials
Cytarabine
Appointments and Schedules
Deoxycytidine Kinase
Neoplasms
Leukemia L1210
Clinical Trials, Phase I
Deamination
Maximum Tolerated Dose
National Cancer Institute (U.S.)
DNA
Tumor Cell Line
Heterografts
Human Activities
Antineoplastic Agents
Toxicology
Gastrointestinal Tract
Leukemia

Keywords

  • 5-azacytidine
  • arabinosyl-5-azacytosine
  • cytosine arabinoside
  • deoxycytidine kinase

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Grem, J. L., Shoemaker, D. D., Hoth, D. F., King, S. A., Plowman, J., Zaharko, D., ... Leyland-Jones, B. (1987). Arabinosyl-5-azacytosine: A novel nucleoside entering clinical trials. Investigational New Drugs, 5(4), 315-328. https://doi.org/10.1007/BF00169970

Arabinosyl-5-azacytosine : A novel nucleoside entering clinical trials. / Grem, Jean L; Shoemaker, D. Dale; Hoth, Daniel F.; King, Susan A.; Plowman, Jacqueline; Zaharko, Daniel; Grieshaber, Charles K.; Harrison, Steadman D.; Cradock, James C.; Leyland-Jones, Brian.

In: Investigational New Drugs, Vol. 5, No. 4, 01.12.1987, p. 315-328.

Research output: Contribution to journalReview article

Grem, JL, Shoemaker, DD, Hoth, DF, King, SA, Plowman, J, Zaharko, D, Grieshaber, CK, Harrison, SD, Cradock, JC & Leyland-Jones, B 1987, 'Arabinosyl-5-azacytosine: A novel nucleoside entering clinical trials', Investigational New Drugs, vol. 5, no. 4, pp. 315-328. https://doi.org/10.1007/BF00169970
Grem JL, Shoemaker DD, Hoth DF, King SA, Plowman J, Zaharko D et al. Arabinosyl-5-azacytosine: A novel nucleoside entering clinical trials. Investigational New Drugs. 1987 Dec 1;5(4):315-328. https://doi.org/10.1007/BF00169970
Grem, Jean L ; Shoemaker, D. Dale ; Hoth, Daniel F. ; King, Susan A. ; Plowman, Jacqueline ; Zaharko, Daniel ; Grieshaber, Charles K. ; Harrison, Steadman D. ; Cradock, James C. ; Leyland-Jones, Brian. / Arabinosyl-5-azacytosine : A novel nucleoside entering clinical trials. In: Investigational New Drugs. 1987 ; Vol. 5, No. 4. pp. 315-328.
@article{0adbe187e49a48f6bf134abe42f4eb63,
title = "Arabinosyl-5-azacytosine: A novel nucleoside entering clinical trials",
abstract = "Arabinosyl-5-azacytosine is a new compound which has been selected by the Division of Cancer Treatment, National Cancer Institute for clinical development as an antineoplastic agent based on its high degree of activity against a broad range of tumor types in preclinical studies. Therapeutic activity has been observed against murine and human leukemias, transplantable murine solid tumors, and human tumor xenografts. Arabinosyl-5-azacytosine exhibited a broader spectrum of activity against human solid tumors than cytosine arabinoside. Arabinosyl-5-azacytosine is phosphorylated to the nucleotide level by deoxycytidine kinase. Upon further anabolism to the triphosphate level, it can be incorporated into DNA. The mechanism of cytotoxicity is thought to be related to inhibition of DNA synthesis. Leukemic and solid tumor cell lines that are resistant to cytosine arabinoside due to deletion of deoxycytidine kinase activity are cross-resistant to arabinosyl-5-azacytosine. Unlike cytosine arabinoside, arabinosyl-5-azacytosine does not readily undergo deamination. Schedule dependence has been demonstrated in mice bearing L1210 leukemia, with superior activity seen with multiple doses administered on each treatment day compared to administration of larger but less frequently administered doses. From preliminary data in solid tumor models, however, antitumor activity did not appear to be superior with continuous infusion compared to that observed on a bolus schedule. Preclinial toxicology studies indicated that the bone marrow and gastrointestinal tract were the main target organs. A single large dose of arabinosyl-5-azacytosine could be tolerated by both mice and dogs. When administered as a continuous infusion, the toxicity was related to both the dose and duration of exposure, suggesting that toxicity resulted from a critical time above a threshold concentration as opposed to the total area under the concentration-time curve. Phase I clinical trials have been initiated to determine the maximum tolerated dose on a low dose continuous infusion schedule for 72 hours and also on a high dose short infusion daily times five schedule.",
keywords = "5-azacytidine, arabinosyl-5-azacytosine, cytosine arabinoside, deoxycytidine kinase",
author = "Grem, {Jean L} and Shoemaker, {D. Dale} and Hoth, {Daniel F.} and King, {Susan A.} and Jacqueline Plowman and Daniel Zaharko and Grieshaber, {Charles K.} and Harrison, {Steadman D.} and Cradock, {James C.} and Brian Leyland-Jones",
year = "1987",
month = "12",
day = "1",
doi = "10.1007/BF00169970",
language = "English (US)",
volume = "5",
pages = "315--328",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "4",

}

TY - JOUR

T1 - Arabinosyl-5-azacytosine

T2 - A novel nucleoside entering clinical trials

AU - Grem, Jean L

AU - Shoemaker, D. Dale

AU - Hoth, Daniel F.

AU - King, Susan A.

AU - Plowman, Jacqueline

AU - Zaharko, Daniel

AU - Grieshaber, Charles K.

AU - Harrison, Steadman D.

AU - Cradock, James C.

AU - Leyland-Jones, Brian

PY - 1987/12/1

Y1 - 1987/12/1

N2 - Arabinosyl-5-azacytosine is a new compound which has been selected by the Division of Cancer Treatment, National Cancer Institute for clinical development as an antineoplastic agent based on its high degree of activity against a broad range of tumor types in preclinical studies. Therapeutic activity has been observed against murine and human leukemias, transplantable murine solid tumors, and human tumor xenografts. Arabinosyl-5-azacytosine exhibited a broader spectrum of activity against human solid tumors than cytosine arabinoside. Arabinosyl-5-azacytosine is phosphorylated to the nucleotide level by deoxycytidine kinase. Upon further anabolism to the triphosphate level, it can be incorporated into DNA. The mechanism of cytotoxicity is thought to be related to inhibition of DNA synthesis. Leukemic and solid tumor cell lines that are resistant to cytosine arabinoside due to deletion of deoxycytidine kinase activity are cross-resistant to arabinosyl-5-azacytosine. Unlike cytosine arabinoside, arabinosyl-5-azacytosine does not readily undergo deamination. Schedule dependence has been demonstrated in mice bearing L1210 leukemia, with superior activity seen with multiple doses administered on each treatment day compared to administration of larger but less frequently administered doses. From preliminary data in solid tumor models, however, antitumor activity did not appear to be superior with continuous infusion compared to that observed on a bolus schedule. Preclinial toxicology studies indicated that the bone marrow and gastrointestinal tract were the main target organs. A single large dose of arabinosyl-5-azacytosine could be tolerated by both mice and dogs. When administered as a continuous infusion, the toxicity was related to both the dose and duration of exposure, suggesting that toxicity resulted from a critical time above a threshold concentration as opposed to the total area under the concentration-time curve. Phase I clinical trials have been initiated to determine the maximum tolerated dose on a low dose continuous infusion schedule for 72 hours and also on a high dose short infusion daily times five schedule.

AB - Arabinosyl-5-azacytosine is a new compound which has been selected by the Division of Cancer Treatment, National Cancer Institute for clinical development as an antineoplastic agent based on its high degree of activity against a broad range of tumor types in preclinical studies. Therapeutic activity has been observed against murine and human leukemias, transplantable murine solid tumors, and human tumor xenografts. Arabinosyl-5-azacytosine exhibited a broader spectrum of activity against human solid tumors than cytosine arabinoside. Arabinosyl-5-azacytosine is phosphorylated to the nucleotide level by deoxycytidine kinase. Upon further anabolism to the triphosphate level, it can be incorporated into DNA. The mechanism of cytotoxicity is thought to be related to inhibition of DNA synthesis. Leukemic and solid tumor cell lines that are resistant to cytosine arabinoside due to deletion of deoxycytidine kinase activity are cross-resistant to arabinosyl-5-azacytosine. Unlike cytosine arabinoside, arabinosyl-5-azacytosine does not readily undergo deamination. Schedule dependence has been demonstrated in mice bearing L1210 leukemia, with superior activity seen with multiple doses administered on each treatment day compared to administration of larger but less frequently administered doses. From preliminary data in solid tumor models, however, antitumor activity did not appear to be superior with continuous infusion compared to that observed on a bolus schedule. Preclinial toxicology studies indicated that the bone marrow and gastrointestinal tract were the main target organs. A single large dose of arabinosyl-5-azacytosine could be tolerated by both mice and dogs. When administered as a continuous infusion, the toxicity was related to both the dose and duration of exposure, suggesting that toxicity resulted from a critical time above a threshold concentration as opposed to the total area under the concentration-time curve. Phase I clinical trials have been initiated to determine the maximum tolerated dose on a low dose continuous infusion schedule for 72 hours and also on a high dose short infusion daily times five schedule.

KW - 5-azacytidine

KW - arabinosyl-5-azacytosine

KW - cytosine arabinoside

KW - deoxycytidine kinase

UR - http://www.scopus.com/inward/record.url?scp=0023636576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023636576&partnerID=8YFLogxK

U2 - 10.1007/BF00169970

DO - 10.1007/BF00169970

M3 - Review article

VL - 5

SP - 315

EP - 328

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 4

ER -